The pharmaceutical giant has reached a pivotal milestone in its mission to replace aging blockbusters with a more potent generation of protein degradation therapies.
Breakthrough through protein “tagging” technology
On March 9, Bristol Myers Squibb confirmed that its experimental therapy, mezigdomide, met primary endpoints in a Phase 3 clinical trial. When integrated into standard care regimens, the drug demonstrated a “statistically and clinically meaningful” improvement in progression-free survival for patients with relapsed or refractory multiple myeloma.
Mezigdomide belongs to a class known as CELMoDs, which utilize selective protein degradation. Unlike traditional inhibitors that merely block protein activity, these agents “tag” problematic proteins for complete removal by the body’s natural processes. This advanced mechanism is designed to be more potent and overcome the drug resistance often seen with predecessors like Revlimid and Pomalyst.
Strategic transition and growth prospects
The success of mezigdomide, coupled with iberdomide currently under FDA review (with a decision expected in August), bolsters Bristol Myers’ strategy to navigate upcoming patent expirations. This “data-rich” period is seen as essential for reassuring investors about the company’s future value.
Market analysts highlight the CELMoD program as a critical long-term growth engine. A key study directly comparing mezigdomide to Pomalyst, expected in 2027, will be instrumental in supporting a smooth brand transition and maintaining the company’s leadership in the hematology oncology market.